126 related articles for article (PubMed ID: 38794986)
1. Factors contributing to the clinical effectiveness of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus.
Hagi K; Kochi K; Watada H; Kaku K; Ueki K
J Diabetes Investig; 2024 May; ():. PubMed ID: 38794986
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Dubourg J; Ueki K; Grouin JM; Fouqueray P
Diabetes Obes Metab; 2021 Mar; 23(3):800-810. PubMed ID: 33275318
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
Reilhac C; Dubourg J; Thang C; Grouin JM; Fouqueray P; Watada H
Diabetes Obes Metab; 2022 May; 24(5):838-848. PubMed ID: 34984815
[TBL] [Abstract][Full Text] [Related]
4. Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials.
Hagi K; Kochi K; Watada H; Kaku K; Ueki K
J Diabetes Investig; 2023 Sep; 14(9):1101-1109. PubMed ID: 37264517
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.
Dubourg J; Fouqueray P; Thang C; Grouin JM; Ueki K
Diabetes Care; 2021 Apr; 44(4):952-959. PubMed ID: 33574125
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Hagi K; Nitta M; Watada H; Kaku K; Ueki K
J Diabetes Investig; 2023 Nov; 14(11):1246-1261. PubMed ID: 37610062
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Dubourg J; Fouqueray P; Quinslot D; Grouin JM; Kaku K
Diabetes Obes Metab; 2022 Apr; 24(4):609-619. PubMed ID: 34866306
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy.
Fouqueray P; Pirags V; Diamant M; Schernthaner G; Lebovitz HE; Inzucchi SE; Bailey CJ
Diabetes Care; 2014 Jul; 37(7):1924-30. PubMed ID: 24722500
[TBL] [Abstract][Full Text] [Related]
9. Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.
Theurey P; Thang C; Pirags V; Mari A; Pacini G; Bolze S; Hallakou-Bozec S; Fouqueray P
Endocrinol Diabetes Metab; 2022 Nov; 5(6):e371. PubMed ID: 36239048
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials.
Singh AK; Singh A; Singh R; Misra A
Diabetes Metab Syndr; 2023 Feb; 17(2):102710. PubMed ID: 36702046
[TBL] [Abstract][Full Text] [Related]
11. Differences in imeglimin response in subgroups of patients with type 2 diabetes stratified by data-driven cluster analysis: A post-hoc analysis of imeglimin clinical trial data.
Hagi K; Kochi K; Watada H; Kaku K; Ueki K
Diabetes Obes Metab; 2024 Jun; ():. PubMed ID: 38924336
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.
Abdelhaleem IA; Salamah HM; Alsabbagh FA; Eid AM; Hussien HM; Mohamed NI; Ebada MA
Diabetes Metab Syndr; 2021; 15(6):102323. PubMed ID: 34717136
[TBL] [Abstract][Full Text] [Related]
13. Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes.
Pacini G; Mari A; Fouqueray P; Bolze S; Roden M
Diabetes Obes Metab; 2015 Jun; 17(6):541-545. PubMed ID: 25694060
[TBL] [Abstract][Full Text] [Related]
14. Different doses of imeglimin for management of type 2 diabetes mellitus: a systematic review, meta-analysis, and meta-regression of randomized clinical trials.
Permana H; Soetedjo NNM; Yanto TA; Tendean M; Hariyanto TI; Suastika K
Expert Rev Endocrinol Metab; 2024; 19(1):89-98. PubMed ID: 38047423
[TBL] [Abstract][Full Text] [Related]
15. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients.
Pirags V; Lebovitz H; Fouqueray P
Diabetes Obes Metab; 2012 Sep; 14(9):852-8. PubMed ID: 22519919
[TBL] [Abstract][Full Text] [Related]
16. Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Nomoto H; Takahashi A; Nakamura A; Kurihara H; Takeuchi J; Nagai S; Taneda S; Miya A; Kameda H; Cho KY; Miyoshi H; Atsumi T
BMJ Open Diabetes Res Care; 2022 Nov; 10(6):. PubMed ID: 36379585
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial.
Osonoi T; Shirabe S; Saito M; Hosoya M; Douguchi S; Ofuchi K; Katoh M
Front Pharmacol; 2023; 14():1205021. PubMed ID: 37351507
[No Abstract] [Full Text] [Related]
18. Imeglimin: a new antidiabetic drug with potential future in the treatment of patients with type 2 diabetes.
Nowak M; Grzeszczak W
Endokrynol Pol; 2022; 73(2):361-370. PubMed ID: 35381095
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Fouqueray P; Pirags V; Inzucchi SE; Bailey CJ; Schernthaner G; Diamant M; Lebovitz HE
Diabetes Care; 2013 Mar; 36(3):565-8. PubMed ID: 23160726
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects.
Fouqueray P; Chevalier C; Bolze S
Clin Drug Investig; 2022 Sep; 42(9):721-732. PubMed ID: 35867199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]